Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 14/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5638146 | 0.99 | CNR1 (0.46) | CNR1PYGLDRD3HRH4EHMT2 | |
| SCHEMBL5640239 | 0.93 | ALOX15 (0.41) | CNR1PYGL | |
| SCHEMBL5642478 | 0.93 | PYGL (0.46) | CNR1PYGLDRD3EHMT2 | |
| SCHEMBL5643086 | 0.89 | KDM4E (0.48) | DRD3 | |
| SCHEMBL5640430 | 0.88 | F10 (0.36) | CNR1 | |
| SCHEMBL5638730 | 0.86 | HRH4 (0.47) | CNR1PYGLHRH4HRH3 | |
| SCHEMBL5643133 | 0.84 | BCHE (0.43) | — | |
| SCHEMBL5640479 | 0.84 | CNR1 (0.53) | CNR1PYGLDRD3HRH4HRH3 | |
| SCHEMBL5642077 | 0.83 | F10 (0.45) | — | |
| SCHEMBL5641220 | 0.82 | ENPP2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199149-B2 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMANY | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | F2, F12, SPINT2 | CNR1 2663/4885PYGL 1786/4885DRD3 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.